Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 4, 2011, Pages 642-650

  Binns, David S ^a   Pirzkall, Andrea ^b   Yu, Wei ^b   Callahan, Jason ^a   Mileshkin, Linda ^a   Conti, Peter ^c   Scott, Andrew M ^d   MacFarlane, David ^e   Fine, Bernard M ^b   Hicks, Rodney J ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Compliance; Erlotinib therapy; Non small cell lung cancer; PET acquisition protocols

Indexed keywords

3' FLUOROTHYMIDINE F 18; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEHYDRATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG UPTAKE; FATIGUE; FEASIBILITY STUDY; FEVER; GLUCOSE BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REPRODUCIBILITY; TREATMENT RESPONSE;

BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; GUIDELINE ADHERENCE; HUMANS; INTERNATIONALITY; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; QUINAZOLINES; TREATMENT OUTCOME;

EID: 79953715140     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1665-0     Document Type: Article

References (19)

1. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
2. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 122S 150S 19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D
3. R Tuma 2006 Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints J Natl Cancer Inst 98 1272 1274 16985244 10.1093/jnci/djj403
4. J Vansteenkiste BM Fischer C Dooms J Mortensen 2004 Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Lancet Oncol 5 531 540 15337482 10.1016/S1470-2045(04)01564-5 (Pubitemid 39194041)
5. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782 10673991 10.1016/S0959- 8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D (Pubitemid 29512308)
6. H Barthel MC Cleij DR Collingridge OC Hutchinson S Osman Q He, et al. 2003 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Res 63 3791 3798 12839975 1:CAS:528:DC%2BD3sXltVGqs78%3D (Pubitemid 36793068)
7. AJ de Langen B Klabbers M Lubberink R Boellaard MD Spreeuwenberg BJ Slotman, et al. 2009 Reproducibility of quantitative 18F-3′-deoxy- 3′-fluorothymidine measurements using positron emission tomography Eur J Nucl Med Mol Imaging 36 389 395 18931838 10.1007/s00259-008-0960-5
8. AF Shields JM Lawhorn-Crews DA Briston S Zalzala S Gadgeel KA Douglas, et al. 2008 Analysis and reproducibility of 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer Clin Cancer Res 14 4463 4468 18628460 10.1158/1078-0432.CCR-07- 5243 1:CAS:528:DC%2BD1cXosFGit7Y%3D
9. C Nahmias LM Wahl 2008 Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors J Nucl Med 49 1804 1808 18927325 10.2967/jnumed.108.054239
10. WA Weber SI Ziegler R Thödtmann AR Hanauske M Schwaiger 1999 Reproducibility of metabolic measurements in malignant tumors using FDG PET J Nucl Med 40 1771 1777 10565769 1:STN:280:DC%2BD3c%2FivFCquw%3D%3D (Pubitemid 29523568)
11. H Minn KR Zasadny LE Quint RL Wahl 1995 Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET Radiology 196 167 173 7784562 1:STN:280:DyaK2MzgsVSiuw%3D%3D
12. LK Shankar JM Hoffman S Bacharach MM Graham J Karp AA Lammertsma, et al. 2006 Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 1059 1066 16741317 1:CAS:528:DC%2BD28XmtlWmt7s%3D (Pubitemid 46939960)
13. R Boellaard MJ O'Doherty WA Weber FM Mottaghy MN Lonsdale SG Stroobants, et al. 2010 FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 181 200 19915839 10.1007/s00259-009-1297-4
14. Erlotinib (Tarceva®) (package insert). South San Francisco: Genentech, Inc., 2007.
15. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
16. Calvert H, Twelves C, Ranson M, Anthoney A, Plummer R, Fettner S, et al. The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: preliminary results. J Clin Oncol 2005;23 (June 1 Supplement):3076.
17. LM Velasquez R Boellaard G Kollia W Hayes OS Hoekstra AA Lammertsma, et al. 2009 Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies J Nucl Med 50 1646 1654 19759105 10.2967/jnumed.109.063347 1:CAS:528:DC%2BD1MXhtlehsbjF
18. S Beaulieu P Kinahan J Tseng LK Dunnwald EK Schubert P Pham, et al. 2003 SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences J Nucl Med 44 1044 1050 12843218 (Pubitemid 39663378)
19. N Paquet A Albert J Foidart R Hustinx 2004 Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues J Nucl Med 45 784 788 15136627 1:CAS:528:DC%2BD2cXnsFygt7k%3D (Pubitemid 47618557)